Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present Rezdiffra research at AASLD’s The Liver Meeting, taking place November 5–9, 2026, in Denver.
The presentations include 13 real-world evidence abstracts from its RESONANCE program, examining treatment patterns, monitoring, adherence and treatment persistence in routine practice. The largest dataset spans more than 12,000 patients. Clinical abstracts examine noninvasive measures of treatment response, cardiovascular risk markers and patient-reported outcomes. Madrigal said the real-world findings include improvements in noninvasive measures of liver health through 12 months.
Madrigal Pharmaceuticals (MDGL) will release its third-quarter 2026 financial results on November 3, 2026, before U.S. financial markets open.
Management will review financial and operating results in a live webcast at 8 a.m. Eastern Time, accessible through the company’s Investor Relations website. A replay will be available approximately two hours after the live webcast.
Madrigal Pharmaceuticals (MDGL) granted equity inducement awards to 26 new non-executive employees on October 1 and October 14, 2026. The awards total 9,642 time-based restricted stock units under its 2025 Inducement Plan. Approved by the independent Compensation Committee, they vest in four equal installments on the first through fourth grant-date anniversaries, subject to continued employment at each vesting date.
Madrigal Pharmaceuticals (MDGL) announced publication of a Phase 3 analysis showing consistent Rezdiffra effects across common genetic risk variants associated with MASH.
The pre-specified secondary analysis of MAESTRO-NASH, published in the Journal of Hepatology, evaluated whether these variants altered treatment response. Rezdiffra improved fibrosis, or liver scarring, and achieved resolution of metabolic dysfunction-associated steatohepatitis (MASH), alongside liver fat and biomarker reductions. Results extended across patients with PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7 variants. Madrigal said the findings support its pipeline strategy of developing treatments targeting genetic drivers that may complement Rezdiffra in specific patient populations.
Madrigal Pharmaceuticals (MDGL) granted equity inducement awards to 27 new non-executive employees on September 1 and 14, 2026 under its 2025 Inducement Plan.
The awards, approved by the independent Compensation Committee under Nasdaq Rule 5635(c)(4), comprise options to purchase a total of 2,754 shares at an exercise price of $538.71 per share and 16,149 time-based restricted stock units. Options vest 25% after one year and 6.25% quarterly thereafter, while RSUs vest in four equal annual installments, subject to continued employment.
Madrigal Pharmaceuticals (MDGL) will participate in the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 at 1:00 p.m. EDT. The company’s presentation will be webcast live and accessible via Madrigal’s Investor Relations Events and Presentations page, with a replay available after the event.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on August 15, 2026 to 13 new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). The awards total 4,676 time-based restricted stock units, vesting in four equal annual installments over four years, contingent on continued employment.
Madrigal Pharmaceuticals (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Reed is Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson, leading R&D across oncology, immunology, neuroscience and other serious diseases.
According to Madrigal, his extensive scientific, leadership and global drug development experience is expected to support the company as it advances Rezdiffra and its broader MASH pipeline.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on August 1, 2026 to ten new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee in line with Nasdaq Listing Rule 5635(c)(4). The employees received an aggregate of 4,263 time-based restricted stock units, vesting in four equal annual installments over four years, contingent on continued employment at each vesting date.
Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will participate in the Canaccord Genuity Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. EDT. The company’s presentation will be webcast live, with access via Madrigal’s Investor Relations Events and Presentations page, and a replay available after the event.